SCHEMBL29586245

SCHEMBL29586245

COC(=O)[C@@H]1CCN(C(=O)c2cc(-c3cc(OC)ncc3F)[nH]n2)C2(CC2)C1

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ FFAR4 Q5NUL3 1/20 0.37
▸ TBK1 Q9UHD2 4/20 0.35
▸ TLR9 Q9NR96 1/20 0.34
▸ TLR8 Q9NR97 1/20 0.34
▸ TLR7 Q9NYK1 1/20 0.34
▸ EGLN1 Q9GZT9 1/20 0.33
▸ CCR2 P41597 1/20 0.33
▸ MC4R P32245 2/20 0.32
▸ KCNH2 Q12809 1/20 0.32
▸ CRBN Q96SW2 1/20 0.32
▸ FFAR1 O14842 4/20 0.32
▸ PDCD1 Q15116 2/20 0.31
▸ CD274 Q9NZQ7 2/20 0.31
▸ KDM5A P29375 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ CCNE1 P24864 1/20 0.30
▸ CDK2 P24941 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24423911 1.00 FFAR4 (0.37) FFAR4TBK1TLR9TLR8TLR7
SCHEMBL24424523 1.00 FFAR4 (0.37) FFAR4TBK1TLR9TLR8TLR7
SCHEMBL29584891 1.00 FFAR4 (0.37) FFAR4TBK1TLR9TLR8TLR7
SCHEMBL29585040 1.00 FFAR4 (0.37) FFAR4TBK1TLR9TLR8TLR7
SCHEMBL24424524 1.00 FFAR4 (0.37) FFAR4TBK1TLR9TLR8TLR7
SCHEMBL30298786 0.93 ACACB (0.32) FFAR4TBK1KDM5A
SCHEMBL24424096 0.92 FFAR4 (0.40) FFAR4TBK1TLR9TLR8TLR7
SCHEMBL24423491 0.92 FFAR4 (0.40) FFAR4TBK1TLR9TLR8TLR7
SCHEMBL24423493 0.92 FFAR4 (0.40) FFAR4TBK1TLR9TLR8TLR7
SCHEMBL29584337 0.92 FFAR4 (0.40) FFAR4TBK1TLR9TLR8TLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12606541-B2 PPARg modulators and methods of use EISAI R&D MANAGEMENT CO., LTD. (JP) 2026-04-21 — — US disclosed
CN-119156380-A Solid crystalline forms of PPAR-gamma modulators and methods of use thereof 卫材R&D管理有限公司 2024-12-17 — — CN disclosed
EP-4240736-A1 PPAR GAMMA MODULATORS AND METHODS OF USE Eisai R&D Management Co., Ltd. (JP) 2023-09-13 — — EP disclosed
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-03-02 — — US disclosed
WO-2022099144-A1 ΡΡΑRγ MODULATORS AND METHODS OF USE Eisai R&D Mangement Co., Ltd. (JP) 2022-05-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE PPARG, PPARA, PPARD FFAR4 25/4885TBK1 3457/4885TLR9 2630/4885
US-12606541-B2 PPARg modulators and methods of use PPARG, PPARA, PPARD FFAR4 69/4885TBK1 3327/4885TLR9 1783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback